Clinical Trial Update: Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex (TSC) and Neurofibromatosis I (NF1) [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating topical rapamycin for cutaneous manifestations of tuberous sclerosis complex and neurofibromatosis type 1 has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neurofibromatosis Type
• Tuberous Sclerosis Complex

Drugs mentioned

• Rapamycin (sirolimus)

Snippet

Sponsor: The University of Texas Health Science Center, Houston | Conditions: Tuberous Sclerosis, Neurofibromatoses | Phase 1 | Status: COMPLETED